Lung Cancer | Specialty

Dr. Brahmer on the Role of Immunotherapy in Metastatic NSCLC

December 4th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses the role of immunotherapy in the treatment of patients with metastatic non–small cell lung cancer (NSCLC).

ALK+ NSCLC Paradigm Bursting With Frontline Options

December 1st 2018

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

Brahmer Shares Next Steps for Immunotherapy in Metastatic NSCLC

December 1st 2018

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

Immunotherapy May Have Place Among TKI Boom in EGFR+ NSCLC

November 30th 2018

Within the last decade, 4 tyrosine kinase inhibitors have been approved for the frontline treatment of patients with EGFR-positive non–small cell lung cancer.

Evidence Grows for Tumor Mutational Burden as Predictor of Immunotherapy Success

November 29th 2018

Tumor mutational burden has been shown in studies to predict response to immunotherapies in certain types of cancer and is being validated in clinical trials as a biomarker of response.

Expert Highlights Management of Immune-Related Toxicities With NSCLC Treatment

November 29th 2018

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.

Novel Molecular Markers at Forefront of NSCLC Research

November 29th 2018

Ardaman Shergill, MD, discusses the impact of tumor mutational burden, as well as RET and NTRK fusions, in the NSCLC paradigm.

Treatments Emerging for ROS1-, BRAF-Driven Lung Cancers

November 28th 2018

Deepa S. Subramaniam, MBBS, MSc, discusses the complex and evolving treatment paradigm of BRAF- and ROS1-driven non–small cell lung cancer.

Dr. Camidge on Mechanisms of Resistance to TKIs in NSCLC

November 27th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

Brigatinib Approved in Europe for ALK+ NSCLC

November 27th 2018

The European Commission has approved brigatinib (Alunbrig) for the treatment of adult patients with ALK-positive non–small cell lung cancer who were previously treated with crizotinib (Xalkori).

Frontline Data, Resistance Mechanisms Guide Approaches in ALK+ NSCLC

November 27th 2018

Mary Jo Fidler, MD, discusses the latest developments in the treatment of patients with ALK-positive lung cancer.

Nivolumab/Ipilimumab Combo Misses Primary Endpoint in Phase III SCLC Trial

November 27th 2018

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) did not improve overall survival versus placebo as a maintenance therapy for patients with extensive-stage small cell lung cancer without disease progression following frontline platinum-based chemotherapy.

Dr. Drilon Discusses the FDA Approval of Larotrectinib

November 27th 2018

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses the FDA approval larotrectinib in NTRK-positive cancers.

Immunotherapy Arrives in Stage III NSCLC, But Questions Remain

November 26th 2018

Thomas Hensing, MD, discusses the emergence of immunotherapy in the stage III non–small cell lung cancer armamentarium, and questions that must be answered to build on this initial success.

Rudin Reflects on Recent Data in SCLC

November 21st 2018

Charles M. Rudin, MD, PhD, reflects on the latest developments in small cell lung cancer.

Immunotherapy Combos Expand Across Lung Cancer Subtypes

November 21st 2018

Lawrence E. Feldman, MD, discusses exciting new data surrounding immunotherapy combinations in lung cancer.

Superiority of Third-Generation EGFR TKI

November 20th 2018

PACIFIC Trial: Positive New Data in OS & PFS

November 20th 2018

Second-Line after I-O: Where Do We Go from There?

November 20th 2018

Blood-Based TMB as a Predictive Biomarker in NSCLC

November 20th 2018